España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Arcutis Biotherapeutics
ARQT
NASDAQ
Watchlist
Get Report
Perks
Buy
Compare Brokers
$10.77
0.15
1.41%
At Close: -
$10.71
-0.06
-0.56%
After Hours: 7:46 PM EDT
15 minutes delayed
Get Report
Watch
Arcutis Biotherapeutics (ARQT) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock
Arcutis Biotherapeutics Stock (NASDAQ: ARQT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, July 15, 2024
Immutep Up as Combo Therapy Meets Carcinoma Study Goals
Zacks
Wednesday, July 10, 2024
FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years
Vandana Singh
Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Benzinga Insights
Needham Reiterates Buy on Arcutis Biotherapeu...
Benzinga Newsdesk
Tuesday, July 09, 2024
Trading Halt: Halt status updated at 5:15:00 ...
Benzinga Newsdesk
Arcutis Biotherapeutics Says FDA Approved sND...
Benzinga Newsdesk
Trading Halt: Halted at 4:25:38 p.m. ET - Tra...
Benzinga Newsdesk
Arcutis Provides Update On sNDA for Roflumila...
Benzinga Newsdesk
Monday, July 08, 2024
Arcutis Biotherapeutics Announces FDA Approva...
Benzinga Newsdesk
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Avi Kapoor
Monday, June 24, 2024
FDA Expands Argenx's Vyvgart Label to Treat Rare Disorder
Zacks
Thursday, June 20, 2024
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Avi Kapoor
Thursday, June 13, 2024
Avidity Up 33% on Rare Muscle Disease Study Results
Zacks
Monday, June 10, 2024
Arcutis Presents New Long-Term Data Of Roflum...
Benzinga Newsdesk
Wednesday, June 05, 2024
Arcutis Reports Multiple Abstracts, Including...
Benzinga Newsdesk
Wednesday, May 15, 2024
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
Needham Maintains Buy on Arcutis Biotherapeut...
Benzinga Newsdesk
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
Market-Moving News for May 15th
Benzinga Newsdesk
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
Mizuho Maintains Buy on Arcutis Biotherapeuti...
Benzinga Newsdesk
Arcutis Biotherapeutics shares are trading hi...
Benzinga Newsdesk
Tuesday, May 14, 2024
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results
Erica Kollmann
Arcutis Biotherapeutics shares are trading hi...
Benzinga Newsdesk
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
Arcutis Biotherapeutics Q1 2024 Adj EPS $0.32...
Benzinga Newsdesk
Monday, May 13, 2024
The Journal Of Clinical And Aesthetic Dermato...
Benzinga Newsdesk
Friday, April 12, 2024
Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts
Benzinga Insights
Needham Reiterates Buy on Arcutis Biotherapeu...
Benzinga Newsdesk
Wednesday, April 10, 2024
Arcutis Appoints David Topper As Chief Financ...
Benzinga Newsdesk
Monday, March 11, 2024
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
Avi Kapoor
Sunday, Arcutis Biotherapeutics' New Data Fro...
Benzinga Newsdesk
Monday, March 04, 2024
Arcutis Announces Acceptance Of Late Breaking...
Benzinga Newsdesk
Thursday, February 29, 2024
Arcutis Prices $150M Public Offering Of 15,78...
Benzinga Newsdesk
Wednesday, February 28, 2024
Arcutis And Sato Announce Strategic Collabora...
Benzinga Newsdesk
Goldman Sachs Maintains Neutral on Arcutis Bi...
Benzinga Newsdesk
Mizuho Reiterates Buy on Arcutis Biotherapeut...
Benzinga Newsdesk
Breaking Down Arcutis Biotherapeutics: 4 Analysts Share Their Views
Benzinga Insights
Needham Maintains Buy on Arcutis Biotherapeut...
Benzinga Newsdesk
Tuesday, February 27, 2024
Arcutis Biotherapeutics Q4 2023 GAAP EPS $(0....
Benzinga Newsdesk
Arcutis Biotherapeutics Expects Continued Red...
Benzinga Newsdesk
Arcutis Biotherapeutics Q4 GAAP EPS $(0.72) B...
Benzinga Newsdesk
Earnings Scheduled For February 27, 2024
Benzinga Insights
Monday, February 19, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Friday, February 09, 2024
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Thursday, February 01, 2024
Arcutis Biotherapeutics shares are trading hi...
Benzinga Newsdesk
MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Avi Kapoor
Wednesday, January 31, 2024
Steven Cohen Reported 5.2% Passive Stake In A...
Charles Gross
Monday, January 29, 2024
Arcutis Biotherapeutics Announced Journal Of ...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch